Business Context and Reporting Period
Enovis Corporation filed this unaudited Form 10-Q for the quarter ended March 31, 2023. Following the April 2022 separation of ESAB Corporation, Enovis operates as a medical technology company through two reportable segments: Prevention & Recovery and Reconstructive. Prior-period results have been recast to present the fabrication technology business as discontinued operations.
Key Financial Metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net sales | $406.2 million | $375.5 million | +8.2% |
| Gross profit / margin | $235.1 million / 57.9% | $205.9 million / 54.8% | Margin +310 bps |
| Operating loss / margin | $(25.0) million / (6.1%) | $(30.6) million / (8.2%) | Loss improved |
| Net loss from continuing operations | $(22.8) million | $(38.1) million | Improved $15.2 million |
| Net loss attributable to Enovis | $(23.4) million | Net income of $15.1 million | Prior period included $54.4 million discontinued-operations income |
| Continuing-operations diluted EPS | $(0.42) | $(0.71) | Improved $0.29 |
| Adjusted EBITDA | $56.4 million | $47.7 million | +18.2% |
| Adjusted EBITDA margin | 13.9% | 12.7% | +120 bps |
| Operating cash flow | $7.5 million | $(14.4) million | Improved $21.9 million |
| Capital expenditures and intangible purchases | $30.4 million | $24.1 million | Increased |
Prevention & Recovery generated sales of $250.7 million, up 2.4%, and Adjusted EBITDA of $25.7 million, down from $26.4 million. Reconstructive generated sales of $155.4 million, up 19.0%, and Adjusted EBITDA of $30.7 million, up from $21.4 million.
Cash and cash equivalents were $21.9 million at March 31, 2023, compared with $24.3 million at December 31, 2022. Inventory was $439.0 million and trade receivables were $280.7 million. Total debt was $285.0 million, entirely classified as long-term debt at quarter-end, compared with $259.3 million at year-end 2022. The weighted-average borrowing rate was 6.02%, and $615 million remained available under the $900 million revolving credit facility.
Material Changes Versus the Prior Comparable Period
- Sales growth was driven primarily by existing-business volume, pricing and market outperformance, especially in Reconstructive. Acquisitions contributed $1.1 million, while foreign currency translation reduced sales by $5.6 million, or 1.5%.
- Gross profit benefited from higher sales, improved operating leverage, pricing and a $5.0 million reduction in inventory fair-value step-up amortization, partly offset by foreign exchange and supply-chain, logistics and other inflationary costs.
- Selling, general and administrative expense increased $18.7 million, reflecting higher commissions, growth investments, medical-device-regulation costs and inflation. Research and development expense increased $3.4 million.
- Interest expense declined to $5.7 million from $7.1 million, primarily because of lower debt following the ESAB separation-related redemptions and the partial repayment of the term loan.
- Operating cash flow improved, primarily because of the lower continuing-operations loss, lower interest payments and working-capital changes. The prior-year operating cash flow included $9.2 million from discontinued operations.
- The prior-year consolidated results included $54.4 million of after-tax discontinued-operations income from the former fabrication technology business. Q1 2023 discontinued operations produced a $0.3 million loss.
Outlook, Commentary, Risks and Unusual Items
Management stated that its liquidity sources are adequate to fund operations for the next twelve months. No specific revenue, earnings or margin guidance was provided in the filing text.
On March 31, 2023, Enovis agreed to acquire Novastep for cash consideration of €90 million, subject to customary closing conditions and regulatory approvals, with closing expected in the second quarter of 2023. In April 2023, the company also agreed to acquire the SEAL external fixation product line from D.N.E., LLC; that transaction was also expected to close in the second quarter.
The company extinguished the remaining $219.3 million term-loan balance on March 1, 2023 using Revolver borrowings, increasing Revolver debt. The credit agreement requires a maximum total leverage ratio of 4.00:1.00, stepping down to 3.75:1.00 for the quarter ending June 30, 2023 and 3.50:1.00 for the quarter ending June 30, 2024, plus a minimum interest-coverage ratio of 3.00:1.00. Enovis reported compliance as of March 31, 2023.
Key disclosed risks include variable interest rates, foreign exchange exposure, inflation and supply shortages, reliance on distributors and reimbursement, medical-device regulation and product liability, recalls and safety issues, cybersecurity, acquisition integration, impairment of goodwill and intangibles, restructuring execution, litigation, and restrictions under the credit agreement. A 1% hypothetical increase in variable borrowing rates would have increased quarterly interest expense by approximately $0.7 million.
Unusual or non-GAAP items included $2.9 million of restructuring charges, $7.8 million of medical-device-regulation and other costs, $11.6 million of strategic transaction costs, $6.9 million of stock-based compensation, $32.0 million of acquired-intangible amortization and a $7.1 million income-tax benefit. Management reported effective disclosure controls and no material changes in internal control over financial reporting.
Important Facts for Investors to Verify
- Reconcile reported consolidated earnings with continuing operations because the prior-year period included substantial discontinued-operations income from ESAB.
- Assess whether Reconstructive growth and margin improvement offset weaker Prevention & Recovery performance and acquisition-related dilution.
- Monitor Revolver utilization, interest rates and compliance with the leverage covenant step-down beginning June 30, 2023.
- Evaluate cash conversion, elevated inventory of $439.0 million and the company’s ability to fund capital spending and acquisitions with only $21.9 million of cash on hand.
- Verify the timing, purchase price and financing implications of the Novastep and SEAL transactions.
- Distinguish GAAP losses from Adjusted EBITDA, including the substantial costs excluded from the non-GAAP measure.
- Review exposure to foreign currency, medical-device regulation, product liability, reimbursement, supply-chain constraints and pending legal proceedings.